Becton, Dickinson and Company (NYSE:BDX), commonly known as BD, is a leading global medical technology firm founded in 1897 by Maxwell Becton and Fairleigh Dickinson. Headquartered in Franklin Lakes, New Jersey, BD has evolved from a regional syringe manufacturer into a diversified supplier of medical devices, instrument systems and reagents. Over more than a century, the company has gained a reputation for quality and innovation, serving hospitals, clinical laboratories, life science researchers and pharmaceutical organizations worldwide.
BD’s operations are organized into three primary segments: BD Medical, BD Life Sciences and BD Interventional. The BD Medical segment delivers needles and syringes, infusion therapy and injection safety solutions designed to enhance patient comfort and reduce needlestick injuries. BD Life Sciences offers advanced diagnostic and research tools, including flow cytometry, molecular testing, microbiology systems and cellular analysis products. BD Interventional, strengthened by the 2017 acquisition of C.R. Bard, focuses on vascular access, oncology and surgical devices such as catheters, biopsy systems and drainage solutions.
With a presence in over 190 countries, BD operates manufacturing, distribution and research facilities across North America, Europe, Asia-Pacific, Latin America and the Middle East & Africa. This expansive footprint enables the company to collaborate closely with healthcare providers and researchers, addressing regional challenges like infection prevention, chronic disease management and the rise of personalized medicine. BD’s global supply chain emphasizes rigorous quality assurance and regulatory compliance to ensure reliable product availability.
Under the leadership of President and Chief Executive Officer Thomas Polen, who assumed the role in February 2020, BD continues to invest significantly in research and development. Supported by an experienced executive team and board of directors, the company pursues innovations in digital health, advanced diagnostics and minimally invasive therapies. Through strategic partnerships, targeted acquisitions and internal development, BD aims to drive sustainable growth while advancing healthcare delivery and patient safety around the globe.
